Option chain shows key data for Portage Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Portage Biotech.

Portage Biotech (NASDAQ:PRTG) Stock, Option Chain

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Scientist,Pipette,Doppler,Blue,Liquid,In,Test,Tube,Beaker,Laboratory

Biotech

News

Health Care

Movers

Trading Ideas

General

PRTG

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

Why Is Portage Biotech Stock Skyrocketing Friday?

WallStreet.Banks.Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

DBVT

MIST

XTIA

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

nasdaq shutter

LXRX

WOLF

Nasdaq Down 100 Points; Federal Reserve&#39;s Favorite Inflation Gauge Increases More Than Expected

Portage Biotech Inc

Press Releases

"Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential"

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

KAVL

OMEX

PRSO

RJDG

RNAZ

WBUY

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Immuron Limited - American Depositary Shares

Immuron

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Ocean Biomedical

PharmaCyte Biotech

SAB Biotherapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Cantor Fitzgerald

Oppenheimer

Comments

Portage Biotech

Portage Biotech (PRTG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga